Following this purchase, Cosmos Health’s total investment in digital assets has reached $3.1 million, reflecting the combined value of its holdings in Bitcoin and Ethereum.

The Annual General Meeting of shareholders of Fiskars Corporation was held at Finlandia Hall, Congress wing (visiting address: Mannerheimintie 13 e, Entrance lobby M1, Helsinki, Finland) on March 11, ...

In Europe, Eclipse Automation is strengthening its presence in the life sciences market by launching of a new Sales, Business Development, and Engineering Applications Hub in Germany—bringing the ...

The company holds a total of 795,537 of its own shares (SANOMA) including the shares acquired on 11 March 2026. Detailed information concerning the acquisition is attached to this stock exchange ...

TekniPlex Healthcare, a global leader in advanced materials science and precision manufacturing for the medical and healthcare industries, announced its participation at the China International ...

IperMoney stands out in the European fintech landscape as one of the pioneers adopting stablecoin-based technology. This innovation enables near-instant international money transfers, overcoming many ...

Modelo announces its largest investment in college basketball with increased media support and consumer activations nationwide. The brand releases a limited-edition collection of merchandise with SLAM ...

The 2026 Optical Fiber Communications Conference and Exhibition (OFC), the world’s largest annual gathering for optical networking and communications professionals, takes place next week at the Los ...

New Singapore facility integrates flexible and rigid sterile barrier packaging systems development under one roof to simplify and accelerate package design and speed to market (L-R) Roger Prevot, ...

Join engineers and industry leaders at the COMSOL Conference to explore cutting-edge innovation, learn new modeling skills, and build connections within the simulation community.

STELLAR-2, a randomized, double-blind, sham-controlled study, will evaluate the effects of salanersen when initiated ~6 months after onasemnogene abeparvovec-xioi in infants with SMA who received ...

Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing product candidates to treat CNS diseases. Minerva is initiating a confirmatory Phase 3 trial with ...